References

1. Grimm, R. and Rettig, R. Association studies between the agniotensin-converting enzyme insertion/deletion polymorphism and hypertension: still interesting? J. Hypertens, 20:1049-1051, 2002.

2. Jones, A. and Montgomery, H. The gly389arg beta-1 adrenoceptor polymorphism and cardiovascular disease: time for a rethink in the funding of genetic studies? Eu . Heart J. 23:1071-1074, 2002.

3. Ridker, P. M., Hennekens, C. H., and Miletich, J. P. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation 99:999-1004, 2000.

4. Wu, A. H. B. and Tsongalis, G. J. Correlation of selected single nucleotide polymorphisms of coagulation factors to risk for cardiovascular disease. Am. J. Cardiol. 87:1361-1366, 2001.

5. Meade, T. W., Mellows, S., Brozovic, M., et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 2:533-537, 1986.

6. Girelli, D., Russo, C., Ferraresi, P., et al. Polymorphisms in the Factor VII gene and the risk of myocardial infarction in patients with coronary artery disease. N. Engl. J. Med. 343:774-780, 2000.

7. Fellowes, A. P., Brennan, S. O., and George, P. M. Identification and characterization of five new fibrinogen gene polymorphisms. Ann. NY Acad. Sci. 936:536-541, 2001.

8. Green, F. R. Fibrinogen polymorphisms and atherothrombotic disease. Ann. NY Acad. Sci. 936:549-559, 2001.

9. Doggen, C. J. M., Bertina, R. M., Cats, V. M., and Rosendaal, F. R. Fibrinogen polymmorphisms are not associated with the risk of myocardial infarction. Brit. J. Haematol. 110:935-938, 2000.

10. de Maat, M. P., Kastelein, J. J., Jukema, J. W., et al. -455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen. REGRESS group. Arteriosclosis Thromb. Vasc. Biol. 18:265-271, 1998.

11. Ridker, P. M., Vaughan, D. E., Stampfer, M. J., Manson, J. E., and Hennekens, C. H. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 341:1165-1168, 1993.

12. Juhan-Vague, I., Pyke, S. D., Alessi, M. C., Jespersen, J., Haverkate, F., and Thompson, S. G. Fibrinolytic factors and the risk of myocar-dial infarction or sudden death in patients with angina pectoris.

ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 94:2057-2063, 1996.

13. Ye, S., Green, F. R., Scarabin, P. Y., et al. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb. Haemost. 74:837-841, 1995.

14. Iacoviello, L., Burzotta, F., Di Castelnuovo, A., Zilo, F., Marchioli, R., and Donati, M. D. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: a meta analysis. Thromb. Haemost. 80:1029-1030, 1998.

15. Ossei-Gerning, N., Mansfield, M. W., Stickland M. H., Wilson, I. J., and Grant, P. Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. Arteriosclosis Thromb. Vasc. Biol. 17:33-37, 1997.

16. Mizuno, K., Satomura, K., Miyamoto, A., et al. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N. Engl. J. Med. 326:287-291, 1992.

17. George, J. N. Platelets. Lancet 355:1531-1541, 2000.

18. Weiss, E. J., Bray, P. F., Tayback, M., et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N. Engl. J. Med. 334:1090-1094, 1996.

19. Ridker, P. M., Hennekens, C. H., Schmitz, C., Stampfer, M. J., and Lindpaintner, K. PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet 349:385-388, 1997.

20. Rinder, C., Mathew, J. P., Rinder, H. M., et al. for the Multicenter Study of Perioperative Ischemia Research Group. Platelet PIA2 polymorphism and platelet activation are associated with increased troponin I release after cardiopulmonary bypass. Anesthesiology 97:1118-1122, 2002.

21. Lemmer, J. H. Clinical experience in coronary bypass surgery for abciximab-treated patients. Ann. Thorac. Surg. 70:S33-S37, 2000.

22. Juergens, C. P., Yeung, A. C., and Oesterle, S. N. Routine platelet transfusion in patients undergoing emergency coronary bypass surgery after receiving abciximab. Am. J. Cardiol. 80:74-75, 1997.

23. Wheeler, G. L., Braden, G. A., Bray, P. F., Marciniak, S. J., Mascelli, M. A., and Sane, D. C. Reduced inhibition by abciximab in platelets with the PIA1 polymorphism. Am. Heart. J. 143:76-82, 2002.

24. Laule, M., Cascorbi, I., Stangl, V., et al. A1/A2 polymorphism of glycoprotein IIIa and association with excess procedural risk for coronary catheter interventions: a case-controlled study. Lancet. 353:708-712, 1999.

25. Kastrati, A., Koch, W., Gawaz, M., et al. P1A polymorphism of gly-coprotein IIIa and risk of adverse events after coronary stent placement. J. Am. Coll. Cardiol. 36:84-89, 2000.

26. Bottiger, C., Kastrati, A., Koch, W., et al. Polymorphism of platelet glycoprotein IIb and risk of thrombosis and restenosis after coronary stent placement. Am. J. Cardiol. 84:987-991, 1999.

27. Furihata, K., Nugent, D. J., and Kunicki, T. J. Influence of platelet collagen receptor polymorphisms on risk for arterial thrombosis. Arch. Patho. of Lab. Med. 126:305-309, 2002.

28. Kunicki, T. J. The influence of platelet collagen receptor polymorphisms in hemostasis and thrombotic disease. Arteriosclosis Thromb. Vasc. Biol. 22:14-20, 2002.

29. Santoso, S., Kunicki, T. J., Kroll, H., Haberbosch, W., and Gardemann, A. Association of the platelet glycoprotein Ia C807 T gene polymorphism with nonfatal myocardial infarction in younger patients. Blood 93:2449-2453, 1999.

30. Mikkelsson, J., Perola, M., Penttila, A., and Karhunen, P. J. Platelet collagen receptor GPIa (C807T/HPA-5) haplotype is not associated with an increased risk of fatal coronary events in middle-aged men. Atherosclosis 165:111-118, 2002.

31. Von Beckerath, N., Koch, W., Mehilli, J., Bottiger, C., Schomig, A., and Kasatrati, A. Glycoprotein Ia gene C807T polymorphism and risk for major adverse cardiac events within the first 30 days after coronary artery stenting. Blood 95:3297-3301, 2000.

32. Kandzari, D. E. and Goldschmidt-Clermont, P. J. Platelet polymorphisms and ischemic heart disease: moving beyond traditional risk factors. J. Am. Coll. Cardiol. 38:1028-1032, 2001.

33. Corral, J., Gonzalez-Conejero, R., Lozano, M. L., Rivera, J., and Vicente, V. New alleles of the platelet glycoprotein Iba gene. Br. J. Haematol. 103:997-1003, 1998.

34. Mikkelsson. J., Perola, M., Penttila, A., and Karhunen, P. J. Platelet glycoprotein Iba HPA-2 Met/VNTR B haplotype as a genetic predictor of myocardial infarction and sudden cardiac death. Circulation 104:876-880, 2001.

35. Meisel, C., Afshar-Kharghan, V., Cascorbi, I., et al. sequence polymorphism of platelet glycoprotein Iba as a risk factor for coronary artery disease and catheter interventions. J.Am. Coll. Cardiol. 38:1023-1027, 2001.

36. Corral, J., Lozano, M. L., Gonzalez-Conejero, R., et al. common polymorphism flanking the ATG initiator codon of GPIb alpha does not affect expression and is not a major risk factor for arterial thrombosis. Thromb. Haemost. 83:23-28, 2000.

37. Croft, S. A., Samani, N. J., Teare, M. D., et al. Novel platelet membrane glycoprotein VI dimnorphism is a risk factor for myocardial infarction. Circulation 104:1459-1463, 2001.

38. Gerdes, C., Gerdes, L. U., Hansen, P. S., and Faergeman, O. Polymorphisms in the lipoprotein lipase gene and their associations with plasma lipid concentrations in 40-year old danish men. Circulation 92:1765-1769, 1995.

39. Larson, I., Hoffmann, M. M., Ordovas, J. M., Schaefer, E. J., Marz, W., and Kreuzer, J. The lipoprotein lipase HindIII polymorphism: association with total cholesterol and LDL-cholesterol, but not with HDL and triglycerides in 342 females. Clin. Chem. 45:963-968, 1999.

40. Wang, X. T., McCredie, R. M., and Wilcken, D. E. L. Common DNA polymorphisms at the lipoprotein lipase gene: association with severity of coronary artery disease and diabetes. Circulation 93:1339-1345, 1996.

41. Gambino, R., Scaglione, L., Alemanno, N., Pagano, G., and Cassader, M. Human lipoprotein lipase HindIII polymorphism in young patients with myocardial infarction. Metabolism 48:1157-1161, 1999.

42. Anderson, J. L., King, G. J., Bair, T. L., et al. Association of lipopro-tein gene polymorphisms with coronary artery disease. J. Am. Coll. Cardiol. 33:1013-1020, 1999.

43. Sawano, M., Watanabe, Y., Ohmura, H., et al. Potentially protective effects of the Ser 447-ter mutation of the lipoprotein lipase gene against the development of coronary artery disease in Japanese subjects via a beneficial lipid profile. Jpn. Circ. J. 65:310-314, 2001.

44. Raslova, K., Smolkova, B., Vohnout, B., Gasparovic, J., and Frohlich, J. J. Risk factors for athersclerosis in survivors of myocar-dial infarction and their spouses: comparison to controls without personal and family history of atherosclerosis. Metabolism 50:24-29, 2001.

45. Wittrup, H. H., Tybjaerg-Hansen, A., Abildgaard, S., Steffensen, R., Schnohr, P., and Nordestgaard, B. G. A common substitution (Asn291Ser) in lipoprotein lipase is associated with increased risk of ischemic heart disease. J. Clin. Invest. 99:1606-1613, 1997.

46. Mackness, M. I., Mackness, B., Durrington, P. N., et al. Paraoxonase and coronary heart disease. Curr. Opin. Lipid 9:319-324, 1998.

47. Garin, M. C. B., James, R.W., Dussoix, P., et al. Paraoxonase polymorphism met-leu54 is associated with modified serum concentrations of the enzyme: a possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J. Clin. Invest. 99:62-66, 1997.

48. Zama, T., Murata, M., Matsubara, Y., et al. A192 arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increase risk for coronary aratery disease in the Japanese. Arteriosclosis Thromb. Vasc. Biol. 17:3565-3569, 1997.

49. Chen, Q., Reis, S. E., Kammerer, C. M., et al. for the WISE Study Group. Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart Lung, and Blood Institute-sponsored Women's Ischemic Syndrome Evaluation (WISE) Study. Am. J. Hum. Genet. 72:13-22, 2003.

50. Sanghera, D. K., Saha, N., Aston, C. E., and Kamboh, M. I. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arteriosclosis Thromb. Vasc. Biol. 17:1067-1073, 1997.

51. James, R. W., Leviev, I., Ruiz, J., et al. Promoter polymorphism T(-107)C of the paroxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients. Diabetes 49:1390-1393, 2000.

52. Levie, I., Poirier, O., Nicaud, V., et al. High expressor paraoxonase PON1 gene promoter polymorphisms are associated with reduced risk of vascular disease in younger coronary patients. Atherosclosis 161:463-467, 2002.

53. Ferre, N., Tous, M., Paul, A., et al. Paraoxonase gln-arg(192) and leu-met(55) gene polymorphisms and enzyme activity in a population with a low rate of coronary heart disease. Clin. Biochem. 35:197-203, 2002.

54. Heijmans, B. T., Westendorp, R. G., Lagaay, A. M., Knook, D. L., Kluft, C., and Slagboom, P. E. Common paraoxonase gene variants, mortality risk and fatal cardiovascular events in elderly subjects. Atherosclosis 149:91-97, 2000.

55. Osei-Hyiaman, D., Hou, L., Menghai, F., Zhihin, R., Zhiming, Z., and Kano, K. Coronary artery disease risk in Chinese type 2 diabetics: is there a role for paraoxonase 1 gene (Q192R) polymorphism? Eu . J. Endocrinol. 144:639-644, 2001.

56. Odawara, M., Tachi, Y., and Yamashita, K. Paraoxonase polymorphism (gln192-arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 82:2257-2260, 1997.

57. Mackness, B., Davies, G. K., Turkie, W., et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arteriosclosis Thromb. Vasc. Biol. 21:1451-1457, 2001.

58. Sanghere, D. K., Saha, N., Aston, C. E., and Kamboh, M. I. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arteriosclosis Thromb. Vasc. Biol. 17:1067-1073, 1997.

59. Pan, J. P., Lai, S.T., Chiang, S. C., Chou, S. C., and Chiang, A. N. The risk of coronary artery disease in population of Taiwan is associated with cys-ser 311 polymorphism of human paraoxonase (PON)-2 gene. Chin. Med. J. 65:415-421, 2002.

60. Azumi, H., Inoue, N., Takeshita, S., et al. Expression of NADH/NADPH oxidase p22phox in human coronary arteries. Circulation 100:1494-1498, 1999.

61. Cai, H., Duarte, N., Wilcken, D. E., and Wang, X. L. NADH/NADPH oxidase p22 phox C242T polymorphism and coronary artery disease in the Australian population. Eu . J. Clin. Invest. 29:744-748, 1999.

62. Inoue, N., Kawashima, S., Kanazawa, K., Yamada, S., Akita, H., and Yokoyama, M. Polymorphism of the NADH/NADPH oxidase p22 phox gene in patients with coronary artery disease. Circulation 97:135-137, 1998.

63. Guzik, T., West, N. E., Black, E., et al. Functional effect of the C242T polymorphism in the NAD(P)H oxidase p22phox gene on vascular superoxide production in atherosclerosis. Circulation 102:1744-1747, 2000.

64. Li, A., Prasad, A., Mincemoyer, R., et al. Relationship of the C242T p22phox gene polymorphism to angiographic coronary artery disease and endothelial function. Am. J. Med. Genet. 86:57-61, 1999.

65. Cahilly, C., Ballantyne, C. M., Lim, D. S., Gotto, A. M., and Ali, J. A variant of p22phox, involved in generation of reactive oxygen species in the vessel wall, is associated with progression of coronary atherosclerosis. Circ. Res. 86:391-395, 2000.

66. Kinlay, S., Libby, P., and Ganz, P. Endothelial function and coronary artery disease. Curr. Opin. Lipid. 12:383-389, 2001.

67. Hingorani, A. D., Liang, C. F., Fatibene, J., et al. A common variant of the endothelial nitric oxide synthase (glu298asp) is a major risk factor for coronary artery disease in the UK. Circulation 100:1515-1520, 1999.

68. Hibi, K., Ishigami, T., Tamura, K., et al. Endothelial nitric oxide synthase gene polymorphism and acute myocardial infarction. Hypertension 32:521-526, 1998.

69. Sofowora, G., Dishy, V., Xie, H. G., et al. In-vivo effects of glu298asp endothelial nitric oxide synthase polymorphism. Pharmacogenesis 11:809-814, 2001.

70. Colombo, M. G., Andreassi, M. G., Paradossi, U., et al. Evidence for association of a common variant of the endothelial nitric oxide synthase gene (glu298^asp) polymorphism to the presence, extent, and severity of coronary artery disease. Heart 87:525-528, 2002.

71. Nassar, B. A., Bevin, L. D., Johnstone, D. E., et al. Relationship of the glu298asp polymorphism of the endothelial nitric oxide synthase gene and early-onset coronary artery disease. Am. Heart J. 142:586-589, 2001.

72. Wang, C. L., Hsu, L. A., Ko, Y. S., Ko, Y. L., and Lee, Y. H. Lack of association between the glu298asp variant of the endothelia nitric oxide synthase gene and the risk of coronary artery disease among Taiwanese. J. Form. Med. Assoc. 100:736-740, 2001.

73. Granath, B., Taylor, R. R., van Bockxmeer, F. M., and Mamotte, C. D. S. Lack of evidence for association between endothelial nitric oxide synthase gene polymorphisms and coronary artery disease in the Australian Caucasian population. J. Cardiovasc. Risk 8:235-241, 2001.

74. Yoshimura, M., Yasue, H., Nakayama, M., et al. Genetic risk factors for coronary artery spasm: significance of endothelial nitric oxide synthase gene T-789^C and missense Glu298asp variants. J. Invest. Med. 48:367-374, 2000.

75. Sigusch, H. H., Surber, R., Lehmann, M. H., et al. Lack of association between 27-bp repeat polymorphoism in intron 4 of the endothelial nitric oxide synthase gene and the risk of coronary artery disease. Scand. J. Clin. Lab. Invest. 60: 229-235, 2000.

76. Nakagami, H., Ikeda, U., Maeda, Y., et al. Coronary artery disease and endothelial nitric oxide synthase and angiotensin-converting enzyme gene polymorphisms. J. Thromb. Thrombol. 8:191-195, 1999.

77. Alvarez, R., Gonzalez, P., Batalla, A., et al. Association between the NOS3 (-786 T/C) and the ACE (I/D) DNA genotypes and early coronary artery disease. Nitric Oxide 5:343-348, 2001.

78. Higgins, G. A., Large, C. H., Rupniak, H. T., and Barnes, J. C. Apolipoprotein E and Alzheimer's disease: a review of recent studies. Pharmacol. Biochem. Behav. 56:675-685, 1997.

79. Corbo, R. M., Vilardo, T., Ruggeri, M., Gemma, A.T., and Scacchi, R. Apolipoprotein E genotype and plasma levels in coronary artery disease. A case-control study in the Italian population. Clin. Biochem. 32:217-222, 1999.

80. Wilson, P.W., Schaefer, E. J., Larson, M.G., and Ordovas, J. M. Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. Arteriosclosis Thromb. Vasc. Biol. 16:1250-1255, 1996.

81. Frikke-Schmidt, R., Tybjaerg-Hansen, A., Steffensen, R., Jensen, G., and Nordestgaard, B. G. Apolipoprotein E genotype: epsilon32 women are protected while epsilon43 and epsilon44 men are susceptible to ischemic heart disease. J. Am. Coll. Cardiol. 35: 1192-1199, 2000.

82. Lambert, J. C., Brousseau, T., Defosse, V.,et al. Independent association of an APOE gene promoter polymorphism with increased risk of myocardial infarction and decrease APOE plasma concentrations—the ECTIM study. Hum. Mol. Genet. 9:57-61, 2000.

83. Boushey, C.J., Beresford, S. A., Omen, G. S., and Motulsky, A. G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 274:1049-1057, 1995.

84. Dunn, J., Title, L. M., Bata I., et al. Relation of a common mutation in methylenetetrahydrofolate reductase to plasma homocysteine and early onset coronary artery disease. Clin. Biochem. 31:95-100, 1998.

85. Klerk, M., Verhoef, P., Clarke, R., Bloom, H. J., Kok, F. J., and Schouten, E. G. MTHFR 677C^polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 288:2023-2031, 2002.

86. Morimoto, K., Haneda, T., Okamoto, K., Ishida, H., and Kikuchi, K. Methylenetetrahydrofolate reductase gene polymorphism, hyperho-mocysteinemia, and cardiovascular diseases in chronic hemodialy-sis patients. Nephron 90:43-50, 2002.

87. Kelly, P. J., Rosand, J., Kistler, J. P., et al. Homocysteine, MTHFR 677C^T polymorphism, and risk of ischemic stroke: results of a meta-analysis. Neurology 59:529-536, 2002.

88. Shuh, J. R., Bleh, D. J., Frierdich, G. E., McMahon, E. G., and Blaine, E. H. Differential effects of rennin-angiogensin system blockade on atherogenesis in cholesterol-fed rabbits. J. Clin. Invest. 981:1453-1458, 1993.

89. Rigat, B., Hubert, C., Alhenc-Gelas, F., Cambien, F., Corvol, P., and Soubrier, F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J. Clin. Invest. 86:1343-1346, 1990.

90. Cambien, F., Poirier, O., Lecerf, L., et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potential risk factor for myocardial infarction. Nature 359:641-643, 1992.

91. Samani, N. J., Thompson, J. R., O'Toole, L., Channer, K., and Woods, K. L. A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction. Circulation 94:708-712, 1996.

92. Shanmugan, V., Sell, K.W., and Saha, B.K. Mistyping ACE heterozygotes. PCR Methods applic. 3:120-121, 1993.

93. Rice, G. I., Foy, C. A., Grant, P. J. Angiotensin converting enzyme and angiotensin II type 1-receptor gene polymorisms and risk of ischaemic heart disease. Cardiovasc. Res. 41:746-753, 1999.

94. Zee, R.Y. L, Fernandez-Ortiz, A., Macaya, C., Pintor, E., Lindpaintner, K., and Fernandez-Cruz, A. ACE D/I polymorphism and incidence of post-PTCA restenosis: a prospective, angiography-based evaluation. Hypertension 37:851-855, 2001.

95. Amant,C., Bauters, C., Bodart, J. C., et al. D allele of the angiotensin I-converting enzyme is a major risk factor for restenosis after coronary stenting. Circulation 96:56-60, 1997.

96. Okumura, K., Sone, T., Kondo, J.,et al. Quinapril prevents restenosis after coronary stenting in patients with angiotensin-converting enzyme D allele. Circ. J. 66:311-316, 2002.

97. Koch, W., Kastrati, A., Mehilli, J., Bottiger, C., von Beckerath, N., and Schomig, A. Insertion/deletion polymorphis of the angiotensin I-converting enzyme gene is not associated with restenosis after coronary stent placement. Circulation 102:197-202, 2000.

98. Meurice, T., Bauters, C., Hermant, X., et al. Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): a randomised, double-blind, placebo-controlled trial. Lancet 357:1321-1324, 2001.

99. Toyofyuku, M., Imazu, M., Sumii, K., et al. Influence of angiotensino-gen M253T gene polymorphism and an angiotensin converting enzyme inhibitor on restenosis after percutaneous coronary intervention. Atherosclosis 160:339-344, 2002.

100. Candy, G. P., Skudicky, D., Mueller, U. K., et al. Association of left ventricular systolic performance and cavity size with angiotensin-converting enzyme genotype in idiopathic dilated cardiopathy. Am. J. Cardiol. 83:740-744, 1999.

101. McNamara, D. M., Holubkov, R., Janosko, K., et al. Pharmacogenetic interactions between P-blocker therapy and the angiotensin-convert-ing enzyme deletion polymorphism in patients with congestive heart failure. Circulation 103:1644-1648, 2001.

102. Montgomery, H. E., Keeling, P. J., Goldman, J. H., Humphries, S. E., Talmud, P. J., and McKenna, W. J. Lack of association between the insertion/deletion polymorphism of the angioten-converting enzyme gene and idiopathic dilated cardiomyopathy. J. Am. Coll. Cardiol. 25:1627-1631, 1995.

103. Spruth, E., Zurbrugg, H. R., Warnecke, C., et al. Expresion of ACE mRNA in the human atrial myocardium is not dependent on left ventricular function, ACE inhibitor therapy, or the ACE I/D genotype. J. Mol. Med. 77:804-810, 1999.

104. Ogimoto, A., Hamada, M., Nakura, J., Miki, T., and Hiwada, K. Relation between angiotensin-converting enzyme II genotype and atrial fibrillation in Japanese patients with hypertrophic cardiomy-opathy. J. Hum. Genet. 47:184-189, 2002.

105. Niu, T., Chen, X., and Xu, X. Angiotensin converting enzyme gene insertion/deletion polymorphism and cardiovascular disease. Therapeutic inplications. Drugs 62:977-993, 2002.

106. Matsubara, M., Suzuki, M., Fujiwara, T., et al. Angiotensin-convert-ing enzyme I/D polymorphism and hypertension: the Ohasama study. J. Hypertens. 20:1121-1216, 2002.

107. Grimm, R., and Rettig, R. Association studies between the angiotensin-converting enzyme insertion/deletion polymorphism and hypertension: still interesting? J. Hypertens. 20:1049-1051, 2002.

108. Sasaki, M., Oki, T., and Iuchi, A. Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiography studies. J Hypertens. 14:1403-1408, 1996.

109. Ohmichi, N., Iwai, N., Uchida, Y., Shichiri, G., Nakamura, Y., and Kinoshita, M. Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotype. Am. J. Hypertens. 10:951-955, 1997.

110. Zee, R.Y., Solomon, S. D., Ajani, U.A., Pfeffer, M.A., Lindpaintner, K., for the HEART Investigators. A prospective evaluation of the angiotensin-converting enzyme D/I polymorphism and left ventricular remodeling in the "Healing and Early After Reducing Therapy" study. Clin.Genet. 61:21-25, 2002.

111. Tiret, L., Bonnardeaux, A., Poirier, O., et al. Synergistic effects of angiotensin-converting enzyme and angiotensin-II type 1 receptor gene polymorphisms on risk of myocardial infarction. Lancet 344:910-913, 1994.

112. Batalla, A., Alvarez, R., Reguero, J. R., et al. Synergistic effect between apolipoprotein E and angiotensinogen gene polymorphisms in the risk for early myocardial infarction. Clin. Chem. 46:1910-1915, 1999.

113. Hilgers, K. F., Langenfeld, M. R.W., Schlaich, M., Veelken, R., and Schmieder, R. E. 1166 A/C polymorphism of the angiotensin II type 1 receptor gene and the response to short-term infusion of angiotensin II. Circulation 100:1394-1399, 1999.

114. Veglio, F., Tayebati, S. K., Schiavone, D., et al. ^-Adrenergic receptor subtypes in peripheral blood lymphocytes of essential hypertensives. J. Hypertens. 19:1847-1854, 2001.

115. Xie, H. G., Kim, R. B., Stein, C.M., Gainer, J.V, Brown, N.J., and Wood, A.J. Alpha 1A-adrenergic receptor polymorphism: association with ethnicity but not essential hypertension. Pharmacogenetics 9:651-656, 1999.

116. McCaffrey, J.M., Pogue-Geile, M.F., Ferrell, R. E., Petro, N., and Manuck, S. B. Variability within a and P-adrenoreceptor genes as a predictor of cardiovascular function at rest and in response to mental challenge. J. Hypertens. 20:1105-1114, 2002.

117. Heinonen, P., Loulu, M., Pesonen, U., et al. Identification of a three-amino acid deletion in the a2B-adrenergic receptor that is associated with reduced basal metabolic rate in obese subjects. J. Clin. Endocrinol. Metab. 84:2429-2433, 1999.

118. Heinonen, P., Jartti, L., Jarvisalo, M. J., et al. Deletion polymorphism in the a2B-adrenergic receptor gene is associated with flow-mediated dilatation of the brachial artery. Clin. Sci. 103:517-524, 2002.

119. Snapir, A., Heinonen, P., Tuomainen, T. P., et al. An insertion/dete-tion polymorphismis a novel genetic risk factor for acute coronary events. J. Am. Coll. Cardiol. 37:1516-1522, 2001.

120. Small, K. M., Forbes, S. l., Rahman, F. F., Bridges, K. M., and Ligett, S. B. A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors. J. Biol. Chem. 275: 23059-23064, 2000.

121. Hajjar, R.J., and MacRae, C. A. Adrenergic-receptor polymorphisms and heart failure. N. Engl. J. Med. 347:1196-1199, 2002.

122. Podlowski, S., Wenzel, K., Luther, H.P., et al. P1-Adrenoceptor gene variations: a role in idiopathic dilated cardiomyopathy? J. Mol. Med. 78:87-93, 2000.

123. Tesson, F., Charron, P., Peuchmaurd. M., et al. Characterization of unique genetic variant in the P1-adrenoceptor gene and evaluation of its role in idiopathic dilated cardiomyopathy. J. Mol. Cell Cardiol. 31:1025-1032, 1999.

124. White, H.L., Maqbool, A., McMahon, A. D., et al. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals at risk of coronary events. A WOSCOPS substudy. Eu . Heart. J. 23:1087-1092, 2002.

125. Small, K. M., Wagoner, L. E., Levin, A. B., Kardia, S. L.R., and Liggett, S.B. Synergistic polymorphisms of P1- and a1c-adrenergic receptors and the risk of congestive heart failure. N. Engl. J. Med. 347:1135-1142, 2002.

126. Borjesson, M., Magnusson, Y., Hjalmarson, A., and Andersson, B. A novel polymorphism in the gene coding for the beta1-adrenergic receptor associated with survival in patients with heart failure. Eu . Heart J. 21:1853-1858, 2000.

127. Brodde, O. E., Rainer, B., Tellkamp, R., Radke, J., Stefan, D., and Insel, P.A. Blunted cardiac responses to receptor activation in subjects with Thr164Ile P2-adrenoceptors. Circulation 103:1048-1050, 2001.

128. Liggett, S. B., Wagoner, L. E., Craft, L. L., et al. The Ile164 P2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J. Clin. Invest. 102:1534-1539, 1998.

129. Wieczorek, S. J., Wu, A. H. B., and Tsongalis, G. Unpublished data.

Diabetes Sustenance

Diabetes Sustenance

Get All The Support And Guidance You Need To Be A Success At Dealing With Diabetes The Healthy Way. This Book Is One Of The Most Valuable Resources In The World When It Comes To Learning How Nutritional Supplements Can Control Sugar Levels.

Get My Free Ebook


Post a comment